Multiple drug resistance, antimutagenesis and anticarcinogenesis
- 1 December 2005
- journal article
- review article
- Published by Elsevier in Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis
- Vol. 591 (1-2) , 24-33
Abstract
No abstract availableKeywords
Funding Information
- Associazione Italiana per la Ricerca sul Cancro
This publication has 61 references indexed in Scilit:
- Role of Multidrug Resistance Protein 2 (MRP2, ABCC2) in Alkylating Agent Detoxification: MRP2 Potentiates Glutathione S-Transferase A1-1-Mediated Resistance to Chlorambucil CytotoxicityThe Journal of Pharmacology and Experimental Therapeutics, 2004
- Effect of PSC 833, an inhibitor of P-glycoprotein on N-methyl-N-nitrosourea induced mammary carcinogenesis in ratsCarcinogenesis, 2003
- P-glycoprotein: from genomics to mechanismOncogene, 2003
- Loss of Multidrug Resistance Protein 1 Expression and Folate Efflux Activity Results in a Highly Concentrative Folate Transport in Human Leukemia CellsJournal of Biological Chemistry, 2003
- Regulation of biliary drug efflux pump expression by hormones and xenobioticsToxicology, 2001
- Identification and Functional Analysis of Two Novel Mutations in the Multidrug Resistance Protein 2 Gene in Israeli Patients with Dubin-Johnson SyndromeJournal of Biological Chemistry, 2001
- Multidrug resistance and mutagenesisMutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 1993
- Stimulation of bacterial mutagenicity by inhibitors of mammalian cell multidrug resistanceMutation Research Letters, 1991
- Protection by inhibitors of multidrug resistance against mitochondrial mutagenesis in Saccharomyces cerevisiaeEuropean Journal of Cancer, 1990
- Verapamil as a co-mutagen in the Salmonella/mammalian microsome mutagenicity testMutation Research Letters, 1988